Intraocular Sustained Release of EPO-R76E Mitigates Glaucoma Pathogenesis by Activating the NRF2/ARE Pathway

Intraocular Sustained Release of EPO-R76E Mitigates Glaucoma Pathogenesis by Activating the NRF2/ARE Pathway

Erythropoietin (EPO) is neuroprotective in multiple models of neurodegenerative diseases, including glaucoma. EPO-R76E retains the neuroprotective effects of EPO but diminishes the effects on hematocrit. Treatment with EPO-R76E in a glaucoma model increases expression of antioxidant proteins and is...

Full description

Bibliographic Details
Main Authors: Sarah Naguib, Carlisle R. DeJulius, Jon R. Backstrom, Ameer A. Haider, John M. Ang, Andrew M. Boal, David J. Calkins, Craig L. Duvall, Tonia S. Rex
Format: Article
Language:English
Published: MDPI AG 2023-02-01
Series:Antioxidants
Subjects:
NRF2
antioxidant
glaucoma
retinal ganglion cell
neuroprotection
neurodegeneration
Online Access:https://www.mdpi.com/2076-3921/12/3/556

Internet

https://www.mdpi.com/2076-3921/12/3/556

Similar Items